Eraxis (anidulafungin) for serious Candida fungal infections

June 2006

Pfizer will be promoting Eraxis (anidulafungin) for serious Candida fungal infections.

It's similar to Cancidas (caspofungin) and Mycamine (micafungin). These "candins" inhibit formation of the fungal cell wall.

Eraxis is given IV. It will be used for candidemia and seems more effective than fluconazole.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

New guidelines focus on preventing heart attacks and strokes in patients who already have cardiovascular disease
Vaccines mumps in and around Iowa is the largest outbreak in 20 years
Vaccines Prevnar helps curb resistant S. pneumoniae infections in the community
Women's Health Enjuvia is a new synthetic conjugated estrogens tablet
Antidepressants how to switch antidepressants
new methylphenidate PATCH called Daytrana
Vivitrol is a new injectable naltrexone for alcohol dependence
Chantix (varenicline) for smoking cessation
Pediatrics Vusion, a new Rx ointment for diaper rash
Infectious Diseases quinolones being overused for uncomplicated urinary tract infections (UTIs)
Infectious Diseases People will soon be asking what to use for "swimmer's ear"
Infectious Diseases Eraxis (anidulafungin) for serious Candida fungal infections
Thyroid Disorders levothyroxine absorption may depend on gastric acidity
Gastroenterology Oral sodium phosphate bowel preps may harm the kidneys in some patients
Medicare D patients won't lose coverage for a specific drug even if their plan's formulary changes